1
|
Quattrini G, Pievani M, Jovicich J, Aiello M, Bargalló N, Barkhof F, Bartrés‐Faz D, Beltramello A, Pizzini FB, Blin O, Bordet R, Caulo M, Constantinides M, Didic M, Drevelegas A, Ferretti A, Fiedler U, Floridi P, Gros‐Dagnac H, Hensch T, Hoffmann K, Kuijer J, Lopes R, Marra C, Müller BW, Nobili F, Parnetti L, Payoux P, Picco A, Ranjeva J, Roccatagliata L, Rossini PM, Salvatore M, Schonknecht P, Schott BH, Sein J, Soricelli A, Tarducci R, Tsolaki M, Visser PJ, Wiltfang J, Richardson J, Frisoni GB, Marizzoni M, Consortium P. Amygdalar nuclei and hippocampal subfields on MRI: Test‐retest reliability of automated segmentation in old and young healthy volunteers. Alzheimers Dement 2020. [DOI: 10.1002/alz.040322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
2
|
Ribaldi F, Altomare D, Jovicich J, Ferrari C, Picco A, Pizzini FB, Soricelli A, Mega A, Ferretti A, Drevelegas A, Bosch B, Müller BW, Marra C, Cavaliere C, Bartrés-Faz D, Nobili F, Alessandrini F, Barkhof F, Gros-Dagnac H, Ranjeva JP, Wiltfang J, Kuijer J, Sein J, Hoffmann KT, Roccatagliata L, Parnetti L, Tsolaki M, Constantinidis M, Aiello M, Salvatore M, Montalti M, Caulo M, Didic M, Bargallo N, Blin O, Rossini PM, Schonknecht P, Floridi P, Payoux P, Visser PJ, Bordet R, Lopes R, Tarducci R, Bombois S, Hensch T, Fiedler U, Richardson JC, Frisoni GB, Marizzoni M. Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magn Reson Imaging 2020; 76:108-115. [PMID: 33220450 DOI: 10.1016/j.mri.2020.11.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 10/02/2020] [Accepted: 11/14/2020] [Indexed: 01/18/2023]
Abstract
Brain vascular damage accumulate in aging and often manifest as white matter hyperintensities (WMHs) on MRI. Despite increased interest in automated methods to segment WMHs, a gold standard has not been achieved and their longitudinal reproducibility has been poorly investigated. The aim of present work is to evaluate accuracy and reproducibility of two freely available segmentation algorithms. A harmonized MRI protocol was implemented in 3T-scanners across 13 European sites, each scanning five volunteers twice (test-retest) using 2D-FLAIR. Automated segmentation was performed using Lesion segmentation tool algorithms (LST): the Lesion growth algorithm (LGA) in SPM8 and 12 and the Lesion prediction algorithm (LPA). To assess reproducibility, we applied the LST longitudinal pipeline to the LGA and LPA outputs for both the test and retest scans. We evaluated volumetric and spatial accuracy comparing LGA and LPA with manual tracing, and for reproducibility the test versus retest. Median volume difference between automated WMH and manual segmentations (mL) was -0.22[IQR = 0.50] for LGA-SPM8, -0.12[0.57] for LGA-SPM12, -0.09[0.53] for LPA, while the spatial accuracy (Dice Coefficient) was 0.29[0.31], 0.33[0.26] and 0.41[0.23], respectively. The reproducibility analysis showed a median reproducibility error of 20%[IQR = 41] for LGA-SPM8, 14% [31] for LGA-SPM12 and 10% [27] with the LPA cross-sectional pipeline. Applying the LST longitudinal pipeline, the reproducibility errors were considerably reduced (LGA: 0%[IQR = 0], p < 0.001; LPA: 0% [3], p < 0.001) compared to those derived using the cross-sectional algorithms. The DC using the longitudinal pipeline was excellent (median = 1) for LGA [IQR = 0] and LPA [0.02]. LST algorithms showed moderate accuracy and good reproducibility. Therefore, it can be used as a reliable cross-sectional and longitudinal tool in multi-site studies.
Collapse
Affiliation(s)
- Federica Ribaldi
- Laboratory of Alzheimer's Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.
| | - Daniele Altomare
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, Geneva University Hospitals, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Clarissa Ferrari
- Unit of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | | | | | - Anna Mega
- Laboratory of Alzheimer's Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Antonio Ferretti
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy; Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece; Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Beatriz Bosch
- Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain
| | - Bernhard W Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | | | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain
| | - Flavio Nobili
- Dept. of Neuroscience (DINOGMI), University of Genoa, Italy; IRCCS Ospedale Policlinico San Martino Genova, Italy
| | - Franco Alessandrini
- Radiology, Dept. of Diagnostic and Public Health, Verona University, Verona, Italy
| | - Frederik Barkhof
- Centre for Medical Image Computing, Department of Medical Physics and Biomedical Engineering, University College London, London, UK; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands
| | - Helene Gros-Dagnac
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France; Université Toulouse 3 Paul Sabatier, UMR 825 Imagerie Cérébrale et Handicaps Neurologiques, F-31024 Toulouse, France
| | - Jean-Philippe Ranjeva
- Institut de Neurosciences de la Timone (INT), Aix-Marseille Université, CNRS, UMR 7289, 13005 Marseille, France
| | - Jens Wiltfang
- Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University, Göttingen, Germany
| | - Joost Kuijer
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands
| | - Julien Sein
- Institut de Neurosciences de la Timone (INT), Aix-Marseille Université, CNRS, UMR 7289, 13005 Marseille, France
| | | | - Luca Roccatagliata
- IRCCS Ospedale Policlinico San Martino Genova, Italy; Dept. of Health Sciences (DISSAL), University of Genoa, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | - Magda Tsolaki
- 1st Department of Neurology, Aristotle University of Thessaloniki, Makedonia, Greece
| | | | | | | | - Martina Montalti
- Laboratory of Alzheimer's Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Massimo Caulo
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy; Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Mira Didic
- APHM, Timone, Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France; Aix Marseille Univ, INSERM, INS, Inst Neurosci Syst, Marseille, France
| | - Núria Bargallo
- Department of Neuroradiology and Magnetic Resonance Image Core Facility, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
| | - Olivier Blin
- Aix Marseille University, UMR-INSERM 1106, Service de Pharmacologie Clinique, AP-HM, Marseille, France
| | - Paolo M Rossini
- Dept. Neuroscience & Neurorehabilitation, IRCCS-San Raffaele-Pisana, Rome, Italy
| | - Peter Schonknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany
| | - Piero Floridi
- Neuroradiology Unit, Perugia General Hospital, Perugia, Italy
| | - Pierre Payoux
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France
| | - Pieter Jelle Visser
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
| | - Régis Bordet
- Univ. Lille, INSERM, CHU Lille, Lille Neuroscience & Cognition - Degenerative and Vascular Cognitive Disorders-U1172. F-59000 Lille, France
| | - Renaud Lopes
- Univ. Lille, INSERM, CHU Lille, Lille Neuroscience & Cognition - Degenerative and Vascular Cognitive Disorders-U1172. F-59000 Lille, France
| | | | - Stephanie Bombois
- Univ. Lille, INSERM, CHU Lille, Lille Neuroscience & Cognition - Degenerative and Vascular Cognitive Disorders-U1172. F-59000 Lille, France
| | - Tilman Hensch
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jill C Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, United Kingdom
| | - Giovanni B Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, Geneva University Hospitals, Geneva, Switzerland
| | - Moira Marizzoni
- Laboratory of Alzheimer's Neuroimaging and Alzheimer's Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| |
Collapse
|
3
|
Quattrini G, Pievani M, Jovicich J, Aiello M, Bargalló N, Barkhof F, Bartres-Faz D, Beltramello A, Pizzini FB, Blin O, Bordet R, Caulo M, Constantinides M, Didic M, Drevelegas A, Ferretti A, Fiedler U, Floridi P, Gros-Dagnac H, Hensch T, Hoffmann KT, Kuijer JP, Lopes R, Marra C, Müller BW, Nobili F, Parnetti L, Payoux P, Picco A, Ranjeva JP, Roccatagliata L, Rossini PM, Salvatore M, Schonknecht P, Schott BH, Sein J, Soricelli A, Tarducci R, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Frisoni GB, Marizzoni M. Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. Neuroimage 2020; 218:116932. [PMID: 32416226 DOI: 10.1016/j.neuroimage.2020.116932] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2020] [Revised: 05/05/2020] [Accepted: 05/07/2020] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The amygdala and the hippocampus are two limbic structures that play a critical role in cognition and behavior, however their manual segmentation and that of their smaller nuclei/subfields in multicenter datasets is time consuming and difficult due to the low contrast of standard MRI. Here, we assessed the reliability of the automated segmentation of amygdalar nuclei and hippocampal subfields across sites and vendors using FreeSurfer in two independent cohorts of older and younger healthy adults. METHODS Sixty-five healthy older (cohort 1) and 68 younger subjects (cohort 2), from the PharmaCog and CoRR consortia, underwent repeated 3D-T1 MRI (interval 1-90 days). Segmentation was performed using FreeSurfer v6.0. Reliability was assessed using volume reproducibility error (ε) and spatial overlapping coefficient (DICE) between test and retest session. RESULTS Significant MRI site and vendor effects (p < .05) were found in a few subfields/nuclei for the ε, while extensive effects were found for the DICE score of most subfields/nuclei. Reliability was strongly influenced by volume, as ε correlated negatively and DICE correlated positively with volume size of structures (absolute value of Spearman's r correlations >0.43, p < 1.39E-36). In particular, volumes larger than 200 mm3 (for amygdalar nuclei) and 300 mm3 (for hippocampal subfields, except for molecular layer) had the best test-retest reproducibility (ε < 5% and DICE > 0.80). CONCLUSION Our results support the use of volumetric measures of larger amygdalar nuclei and hippocampal subfields in multisite MRI studies. These measures could be useful for disease tracking and assessment of efficacy in drug trials.
Collapse
Affiliation(s)
- Giulia Quattrini
- Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
| | - Michela Pievani
- Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Jorge Jovicich
- Center for Mind Brain Sciences, University of Trento, Trento, Italy
| | | | - Núria Bargalló
- Department of Neuroradiology and Image Research Platform, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands; Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, UK
| | - David Bartres-Faz
- Department of Medicine and Health Sciences, Faculty of Medicine, Universitat de Barcelona and IDIBAPS, Barcelona, Spain
| | - Alberto Beltramello
- Department of Radiology, IRCCS "Sacro Cuore-Don Calabria", Negrar, Verona, Italy
| | - Francesca B Pizzini
- Radiology, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
| | - Olivier Blin
- Aix-Marseille University, UMR-INSERM 1106, Service de Pharmacologie Clinique, APHM, Marseille, France
| | - Regis Bordet
- Aix-Marseille Université, INSERM U 1106, 13005, Marseille, France
| | | | | | - Mira Didic
- Aix-Marseille Université, Inserm, Institut de Neurosciences des Systèmes (INS) UMR_S 1106, 13005, Marseille, France; APHM, Timone, Service de Neurologie et Neuropsychologie, Hôpital Timone Adultes, Marseille, France
| | | | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Piero Floridi
- Perugia General Hospital, Neuroradiology Unit, Perugia, Italy
| | - Hélène Gros-Dagnac
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France
| | - Tilman Hensch
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany
| | | | - Joost P Kuijer
- Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands
| | - Renaud Lopes
- INSERM U1171, Neuroradiology Department, University Hospital, Lille, France
| | - Camillo Marra
- Catholic University, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy
| | - Bernhard W Müller
- LVR-Hospital Essen, Department for Psychiatry and Psychotherapy, Faculty of Medicine, University of Duisburg-Essen, Germany
| | - Flavio Nobili
- Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy; IRCCS, Ospedale Policlinico San Martino, Genova, Italy
| | - Lucilla Parnetti
- Section of Neurology, Department of Medicine, University of Perugia, Perugia, Italy
| | - Pierre Payoux
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France
| | - Agnese Picco
- Department of Neuroscience (DINOGMI), University of Genoa, Genoa, Italy
| | | | - Luca Roccatagliata
- IRCCS, Ospedale Policlinico San Martino, Genova, Italy; Department of Health Science (DISSAL), University of Genoa, Genoa, Italy
| | - Paolo M Rossini
- Dept. Neuroscience & Rehabilitation, IRCCS San Raffaele-Pisana, Rome, Italy
| | | | - Peter Schonknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany
| | - Björn H Schott
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Göttingen, Germany; Leibniz Institute for Neurobiology, Magdeburg, Germany; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix-Marseille University, CNRS, Marseille, France
| | | | | | - Magda Tsolaki
- Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Pieter J Visser
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, Netherlands; Maastricht University, Maastricht, Netherlands
| | - Jens Wiltfang
- Department of Psychiatry and Psychotherapy, University Medical Center Goettingen (UMG), Göttingen, Germany; Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal; German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
| | - Jill C Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, United Kingdom
| | - Giovanni B Frisoni
- Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; Memory Clinic and LANVIE-Laboratory of Neuroimaging of Aging, Hospitals and University of Geneva, Geneva, Switzerland
| | - Moira Marizzoni
- Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | | |
Collapse
|
4
|
Jovicich J, Babiloni C, Ferrari C, Marizzoni M, Moretti DV, Del Percio C, Lizio R, Lopez S, Galluzzi S, Albani D, Cavaliere L, Minati L, Didic M, Fiedler U, Forloni G, Hensch T, Molinuevo JL, Bartrés Faz D, Nobili F, Orlandi D, Parnetti L, Farotti L, Costa C, Payoux P, Rossini PM, Marra C, Schönknecht P, Soricelli A, Noce G, Salvatore M, Tsolaki M, Visser PJ, Richardson JC, Wiltfang J, Bordet R, Blin O, Frisoniand GB. Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer’s Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. J Alzheimers Dis 2019; 69:15-35. [DOI: 10.3233/jad-180158] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Jorge Jovicich
- Center for Mind/Brain Sciences, University of Trento, Italy
| | - Claudio Babiloni
- Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, Rome, Italy
- Department of Neuroscience, IRCCS-Hospital San Raffaele Pisana of Rome and Cassino, Rome and Cassino, Italy
| | - Clarissa Ferrari
- Unit of Statistics, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Moira Marizzoni
- Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Davide V. Moretti
- Alzheimer’s Epidemiology and Rehabilitation in Alzheimer’s disease Operative Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | | | - Roberta Lizio
- Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, Rome, Italy
| | - Susanna Lopez
- Department of Physiology and Pharmacology “V. Erspamer”, Sapienza University of Rome, Rome, Italy
| | - Samantha Galluzzi
- Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Diego Albani
- Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Libera Cavaliere
- Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | | | - Mira Didic
- Aix-Marseille Université, INSERM, INS UMR_S 1106, Marseille, France; Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
- APHM, Timone, Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
| | - Ute Fiedler
- Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
| | - Gianluigi Forloni
- Department of Neuroscience, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - Tilman Hensch
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - José Luis Molinuevo
- Alzheimer’s disease and other cognitive disorders unit, Neurology Service, ICN Hospital Clinic i Universitari and Pasqual Maragall Foundation Barcelona, Spain
| | - David Bartrés Faz
- Department of Medicine, Medical Psychology Unit, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain
- Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - Flavio Nobili
- Department of Neuroscience (DINOGMI), Neurology Clinic, University of Genoa, Italy
- U.O. Clinica Neurologica, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - Daniele Orlandi
- Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
| | - Lucilla Parnetti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - Lucia Farotti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - Cinzia Costa
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - Pierre Payoux
- ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, France
| | - Paolo Maria Rossini
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Policlinic A. Gemelli Foundation-IRCCS, Rome, Italy
| | - Camillo Marra
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Policlinic A. Gemelli Foundation-IRCCS, Rome, Italy
| | - Peter Schönknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | | | | | | | - Magda Tsolaki
- 1st University Department of Neurology, AHEPA Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, Greece
| | - Pieter Jelle Visser
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, The Netherlands
| | - Jill C. Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Gunnels Wood Road, Stevenage, UK
| | - Jens Wiltfang
- Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
- Department of Psychiatry and Psychotherapy, LVR-Hospital Essen, Faculty of Medicine, University of Duisburg-Essen, Essen, Germany
- Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August-University, Goettingen, Germany
| | - Régis Bordet
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative and vascular cognitive disorders, Lille, France
| | - Olivier Blin
- Aix Marseille University, UMR-CNRS 7289, Service de Pharmacologie Clinique, AP-HM, Marseille, France
| | - Giovanni B. Frisoniand
- Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | | |
Collapse
|
5
|
Compagnone NA, Blanc B, Picamal P, Galluzzi S, Marizzoni M, Jovicich J, Frisoni GB, Forloni G, Albani D, Richardson J, Parnetti L, Tsolaki M, Nobili F, Bartes-Faz D, Didic M, Schonknecht P, Payoux P, Soricelli A, Rossini P, Visser PJ, Bordet R, Fiedler U, Blin O, Micaleff J, Lanteaume L. P4‐077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG
®
TEST ENABLE STRATIFICATION OF PRE‐DEMENTIA ALZHEIMER'S DISEASE. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.2480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
| | | | | | - Samantha Galluzzi
- Lab Alzheimer's Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, FatebenefratelliBresciaItaly
| | - Moira Marizzoni
- Istituto di Ricovero e Cura a Carattere Scientifico, Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Giovanni B. Frisoni
- Lab Alzheimer's Neuroimaging and Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico, FatebenefratelliBresciaItaly
| | - Gianluigi Forloni
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Diego Albani
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Jill Richardson
- GSK Research and Development, China‐UKHertfordshireUnited Kingdom
| | | | - Magda Tsolaki
- First Department of NeurologyAHEPA University Hospital, MakedoniaThessalonikiGreece
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
| | | | - Pierre Payoux
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | - Andrea Soricelli
- SDN Istituto di Ricerca Diagnostica e Nucleare SpA per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | - Paolo Rossini
- Department of Gerontology, Neurosciences and OrthopedicsCatholic UniversityRomeItaly
| | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
| | - Régis Bordet
- Service de Pharmacologie-Hôpital Huriez-Centre Hospitalier Régional UniversitaireLilleFrance
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Olivier Blin
- Aix-Marseille UniversityCentre National de la Recherche ScientifiqueMarseilleFrance
| | - Joelle Micaleff
- Service de Neurologie et NeuropsychiatryCentre Hospitalier Universitaire la TimoneMarseilleFrance
| | | |
Collapse
|
6
|
Marizzoni M, Ribaldi F, Cattaneo A, Lopizzo N, Galluzzi S, Nobili F, Ranjeva JP, Bartrés-Faz D, Fiedler U, Schonknecht P, Payoux P, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Visser PJ, Albani D, Forloni G, Bordet R, Richardson J, Jovicich J, Blin O, Frisoni GB. O1‐13‐01: ROLE OF THE INFLAMMASOME COMPLEX IN AD‐RELATED HIPPOCAMPAL NEURODEGENERATION IN MCI PATIENTS WITH AD PATHOLOGY. Alzheimers Dement 2018. [DOI: 10.1016/j.jalz.2018.06.3041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Moira Marizzoni
- Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Federica Ribaldi
- Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- University of BresciaBresciaItaly
| | - Annamaria Cattaneo
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Nicola Lopizzo
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Samantha Galluzzi
- Lab Alzheimer's Neuroimaging & Epidemiology, Istituto di Ricovero e Cura a Carattere Scientifico FatebenefratelliBresciaItaly
| | | | - Jean-Philippe Ranjeva
- Clinical Investigation Center - Unit for Clinical Pharmacology and Therapeutic EvaluationCentre Hospitalier Universitaire La Timone, Assistance Publique – Hôpitaux de Marseille, Centre National de la Recherche Scientifique ‐Universite de la MediterraneeMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schonknecht
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipzigGermany
| | - Pierre Payoux
- INSERMImagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | - Andrea Soricelli
- SDN Istituto di Ricerca Diagnostica e Nucleare SpA per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | | | - Magda Tsolaki
- 1st Department of NeurologyAHEPA University Hospital, MakedoniaThessalonikiGreece
| | | | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
| | - Diego Albani
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Gianluigi Forloni
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | - Régis Bordet
- Service de Pharmacologie-Hôpital Huriez- Centre Hospitalier Régional UniversitaireLilleFrance
| | - Jill Richardson
- GSK Research and Development, China‐UKStevenageUnited Kingdom
| | | | - Olivier Blin
- Aix-Marseille University- Centre National de la Recherche ScientifiqueMarseilleFrance
| | - Giovanni B. Frisoni
- Istituto di Ricovero e Cura a Carattere Scientifico Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Universite de GeneveGeneveSwitzerland
| |
Collapse
|
7
|
Raab M, Ria R, Schlenzka J, Krahnke T, Haunschild J, Herrmann F, Fiedler U, Dawson K, Stumpp M, Tadjalli Mehr K, Harstrick A, Vacca A, Goldschmidt H. MP0250 – a dual inhibitor of VEGF and HGF - plus bortezomib + dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.047] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Ribaldi F, Marizzoni M, Jovicich J, Ferrari C, Bosch B, Bartrés‐Faz D, Müller BW, Wiltfang J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva J, Didic M, Gros‐Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargallo N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinides M, Drevelegas A, Rossini PM, Marra C, Schonknecht P, Hensch T, Hoffmann K, Kuijer J, Visser PJ, Barkhof F, Frisoni GB. [P3–062]: ACROSS‐SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI‐SITE 3T STUDY. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
| | - Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology DepartmentIDIBAPSHospital Clínic de BarcelonaBarcelonaSpain
| | | | | | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg‐EssenEssenGermany
| | - Luca Roccatagliata
- Department of NeuroscienceOphthalmology and Genetics University of GenoaGenoaItaly
| | - Agnese Picco
- Neurology Unit, IRCCS AOU San MartinoUniversity of GenoaGenoaItaly
| | | | | | | | - Renaud Lopes
- INSERM U1171 / Neuroradiology DepartmentUniversity HospitalLilleFrance
| | - Regis Bordet
- Service de Pharmacologie‐Hôpital Huriez‐CHRULilleFrance
| | - Julien Sein
- CRMBM‐CEMEREM, UMR 7339Aix Marseille UniversityMarseilleFrance
| | - Jean‐Philippe Ranjeva
- CIC‐UPCET, CHU La Timone, AP‐HM, UMR CNRS‐Universite de la MediterraneeMarseilleFrance
| | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
| | - Helene Gros‐Dagnac
- INSERM. Imagerie Cérébrale Et Handicaps Neurologiquies, UMR825ToulouseFrance
| | | | | | | | | | - Núria Bargallo
- Imaging Diagnostic Center Radiology DepartmentHospital Clínic i Provincial de BarcelonaBarcelonaSpain
| | - Antonio Ferretti
- Department of Neuroscience, Imaging and Clinical SciencesUniversity G. d'AnnunzioChietiItaly
| | | | | | | | | | | | | | - Piero Floridi
- Perugia General HospitalNeuroradiology UnitPerugiaItaly
| | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | | | | | | | - Peter Schonknecht
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipzigGermany
| | | | | | - Joost Kuijer
- VU University Medical CenterAmsterdamNetherlands
| | - Pieter Jelle Visser
- Department of NeurologyAlzheimer Centre, VU Medical CentreAmsterdamNetherlands
- Maastricht UniversityMaastrichtNetherlands
| | - Frederik Barkhof
- Radiology & Nuclear MedicineVU University Medical CenterAmsterdamNetherlands
| | - Giovanni B. Frisoni
- Memory Clinic and LANVIE ‐ Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
- Laboratory of Alzheimer's Neuroimaging and Epidemiology ‐ LANEIRCCS Institute ‐ The Saint John of God Clinical Research CentreBresciaItaly
| |
Collapse
|
9
|
Blanc B, Pelletier N, Biscarrat C, Picamal P, Compagnone N, Galluzzi S, Marizzoni M, Jovicich J, Frisoni GB, Forloni G, Albani D, Richardson J, Parnetti L, Tsolaki M, Nobili F, Bartrez‐faz D, Didic M, Schoenknecht P, Payoux P, Soricelli A, Rossini P, Visser PJ, Bordet R, Fiedler U, Blin O, Dupouey J, Micallef J, Lanteaume L, Michel B. [P3–214]: ADFLAG
®
, A DIAGNOSTIC BLOOD TEST FOR PRE‐DEMENTIA STAGES OF ALZHEIMER's DISEASE. Alzheimers Dement 2017. [DOI: 10.1016/j.jalz.2017.06.1427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
| | | | | | | | | | | | - Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Giovanni B. Frisoni
- Memory Clinic and LANVIE ‐ Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | - Gianluigi Forloni
- Department of NeuroscienceMario Negri Institute for Pharmacological ResearchMilanItaly
| | - Diego Albani
- IRCCS, Istituto di Ricerche Farmacologiche Mario NegriMilanoItaly
| | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - David Bartrez‐faz
- Department of Psychiatry and Clinical Psychobiology, Faculty of MedicineUniversity of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)BarcelonaSpain
| | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
| | - Peter Schoenknecht
- Department of Psychiatry and PsychotherapyUniversity of LeipzigLeipzigGermany
| | - Pierre Payoux
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | - Andrea Soricelli
- Fondazione SDN per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | - Paolo Rossini
- Department of Gerontology, Neurosciences & OrthopedicsCatholic UniversityRomeItaly
| | | | - Regis Bordet
- Service de Pharmacologie‐Hôpital Huriez‐CHRULilleFrance
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg‐EssenEssenGermany
| | - Olivier Blin
- Mediterranean Institute of Cognitive NeurosciencesMarseilleFrance
| | - Julien Dupouey
- Service de Neurologie et Neuropsychologie, CHU la TimoneMarseilleFrance
| | - Joelle Micallef
- Service de Neurologie et Neuropsychologie, CHU la TimoneMarseilleFrance
| | | | - Bernard Michel
- Service de Neurologie Comportementale, Hôpital Sainte MargueriteMarseille, CNRS LNIA UMR 7260 FR3C FR 3512, Aix‐Marseille UniversitéMarseilleFrance
| |
Collapse
|
10
|
Fiedler U, Metz C, Zitt C, Bessey R, Béhé M, Blanc A, Schibli R, Dolado I, Herbst J, Dawson KM, Kiemle-Kallee J. Abstract P4-21-18: Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin®. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2 positivity is an important predictive factor for treatment with anti-HER2 agents in several cancers. However, currently available monoclonal antibody and tyrosine kinase inhibitor drugs rarely achieve full disease control. We have developed a new HER2-targeting molecule with a unique pro-apoptotic mode of action that may provide additional benefit to patients. The DARPin® MP0274* binds to two distinct non-overlapping HER2 epitopes and to human serum albumin for half-life extension. As previously shown**, in vitro, MP0274 induces apoptosis and inhibits proliferation of cells expressing HER2 (IHC3+, IHC2+ and IHC1+) and potently inhibits HER2/HER3 downstream signaling. To support clinical development of MP0274, we tested the potency of MP0274 in several HER2 expressing patient-derived xenograft (PDX) models and investigated tumor localization. In addition, pharmacokinetics (PK) analysis was performed in cynomolgus monkeys.
Methods: Antitumor activity of MP0274 was tested in breast and gastric HER2 expressing PDX mouse models and was compared to standard of care therapies. Tumor localization of MP0274 was studied using an Indium-111 labeled version of MP0274 in a human ovarian adenocarcinoma (SKOV-3) xenograft model by whole-body SPECT/CT imaging. The PK of MP0274 was studied in cynomolgus monkeys (MP0274 is cross-reactive with cynomolgus HER2).
Results: In breast and gastric cancer PDX models, MP0274 showed superior efficacy compared to trastuzumab and lapatinib and equivalent efficacy compared to trastuzumab plus pertuzumab as measured by relative tumor volume. The imaging study with SPECT/CT demonstrated that MP0274 localizes effectively to the HER2-expressing human tumor within 24 h. The PK study in cynomolgus monkeys showed a half-life of ≥5 days at doses of 5 and 10 mg/kg while at the lowest dose tested (1 mg/kg) MP0274 had a terminal half-life of 0.4 days. The PK results are indicative of target-mediated clearance that becomes saturated at doses above 1 mg/kg.
Conclusions: MP0274, with its unique pro-apoptotic mode of action, demonstrates excellent activity in preclinical PDX models, fast localization to tumor and a long half-life in cynomolgus monkeys. MP0274 was well tolerated in all studies. These results suggest that MP0274 has the potential to provide additional clinical benefit to patients with HER2-expressing tumors. A GLP repeated dose toxicology study is ongoing and a phase I clinical trial is in preparation.
* DARPins are small repeat proteins, designed to bind targets with high affinity and specificity, which can be combined in a modular fashion to produce multi-functional agents.
** U. Fiedler et al. SABC 2013. Abstract# 1094 & Poster# P4-12-30.
Citation Format: Fiedler U, Metz C, Zitt C, Bessey R, Béhé M, Blanc A, Schibli R, Dolado I, Herbst J, Dawson KM, Kiemle-Kallee J. Pre-clinical antitumor activity, tumor localization, and pharmacokinetics of MP0274, an apoptosis inducing, biparatopic HER2-targeting DARPin® [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-18.
Collapse
Affiliation(s)
- U Fiedler
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - C Metz
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - C Zitt
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - R Bessey
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - M Béhé
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - A Blanc
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - R Schibli
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - I Dolado
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - J Herbst
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - KM Dawson
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| | - J Kiemle-Kallee
- Molecular Partners AG, Schlieren, Zurich, Switzerland; Paul Scherrer Institut, Center for Radiopharmaceutical Sciences, Villigen, Switzerland; ETH Zurich, Inst. of Pharmaceutical Sciences, Switzerland; F. Hoffmann-La Roche, Basel, Switzerland
| |
Collapse
|
11
|
Dawson K, Feurstein D, Fiedler U, Kuster K, Bez M, Schreiner S, Turner D, Tadjalli Mehr K, Stumpp M, Harstrick A, Baird R, Omlin A, Middleton M, Rodon J, Zitt C. Preliminary biomarker and pharmacokinetic analysis from the completed dose escalation part of the first-in-human Phase I study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF-A, in patients with advanced solid tumors. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)32995-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
12
|
Albi A, Pasternak O, Minati L, Marizzoni M, Bartrés-Faz D, Bargalló N, Bosch B, Rossini PM, Marra C, Müller B, Fiedler U, Wiltfang J, Roccatagliata L, Picco A, Nobili FM, Blin O, Sein J, Ranjeva JP, Didic M, Bombois S, Lopes R, Bordet R, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Frisoni G, Jovicich J. Free water elimination improves test-retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. Hum Brain Mapp 2016; 38:12-26. [PMID: 27519630 DOI: 10.1002/hbm.23350] [Citation(s) in RCA: 61] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 07/11/2016] [Accepted: 08/04/2016] [Indexed: 01/16/2023] Open
Abstract
Free water elimination (FWE) in brain diffusion MRI has been shown to improve tissue specificity in human white matter characterization both in health and in disease. Relative to the classical diffusion tensor imaging (DTI) model, FWE is also expected to increase sensitivity to microstructural changes in longitudinal studies. However, it is not clear if these two models differ in their test-retest reproducibility. This study compares a bi-tensor model for FWE with DTI by extending a previous longitudinal-reproducibility 3T multisite study (10 sites, 7 different scanner models) of 50 healthy elderly participants (55-80 years old) scanned in two sessions at least 1 week apart. We computed the reproducibility of commonly used DTI metrics (FA: fractional anisotropy, MD: mean diffusivity, RD: radial diffusivity, and AXD: axial diffusivity), derived either using a DTI model or a FWE model. The DTI metrics were evaluated over 48 white-matter regions of the JHU-ICBM-DTI-81 white-matter labels atlas, and reproducibility errors were assessed. We found that relative to the DTI model, FWE significantly reduced reproducibility errors in most areas tested. In particular, for the FA and MD metrics, there was an average reduction of approximately 1% in the reproducibility error. The reproducibility scores did not significantly differ across sites. This study shows that FWE improves sensitivity and is thus promising for clinical applications, with the potential to identify more subtle changes. The increased reproducibility allows for smaller sample size or shorter trials in studies evaluating biomarkers of disease progression or treatment effects. Hum Brain Mapp 38:12-26, 2017. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Angela Albi
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Ofer Pasternak
- Departments of Psychiatry and Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ludovico Minati
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Moira Marizzoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni di Dio-FBF, Brescia, Italy
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain
| | - Núria Bargalló
- Department of Neuroradiology and Magnetic Resonance Image core Facility, Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, and IDIBAPS, Barcelona, Spain
| | - Paolo Maria Rossini
- Department Geriatrics Neuroscience & Orthopedics, Catholic University, Policlinic Gemelli, Rome, Italy.,IRCSS S.Raffaele Pisana, Rome, Italy
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | - Bernhard Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jens Wiltfang
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg August University, Göttingen, Germany
| | - Luca Roccatagliata
- Department of Neuroradiology, IRCSS San Martino University Hospital and IST, Genoa, Italy.,Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Flavio Mariano Nobili
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Oliver Blin
- Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS, UMR, Marseille, 7289, France
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix Marseille Université-CNRS, Marseille, France
| | | | - Mira Didic
- APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France.,Aix Marseille Université, Inserm, INS UMR_S 1106, Marseille, 13005, France
| | - Stephanie Bombois
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Renaud Lopes
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Régis Bordet
- Université de Lille, Inserm, CHU Lille, U1171-Degenerative and vascular cognitive disorders, Lille, F-59000, France
| | - Hélène Gros-Dagnac
- INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France.,Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse Cedex 9, France
| | - Pierre Payoux
- INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France.,Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse Cedex 9, France
| | | | | | | | - Antonio Ferretti
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Massimo Caulo
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | | | | | - Andrea Soricelli
- IRCCS SDN, Naples, Italy.,University of Naples Parthenope, Naples, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | | | - Piero Floridi
- Neuroradiology Unit, Perugia General Hospital, Perugia, Italy
| | - Magda Tsolaki
- 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece.,Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Giovanni Frisoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni di Dio-FBF, Brescia, Italy.,Memory Clinic and LANVIE Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | | |
Collapse
|
13
|
Marizzoni M, Pievani M, Pini L, Jovicich J, Nobili F, Ranjeva JP, Bartrés-Faz D, Fiedler U, Schönknech P, Payoux P, Beltramello A, Caulo M, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Visser PJ, Albani D, Forloni G, Bordet R, Richardson J, Blin O, Frisoni GB. IC‐P‐120: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.150] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Lorenzo Pini
- Department of Molecular and Translational Medicine University of BresciaBresciaItaly
- Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Jean-Philippe Ranjeva
- CIC-UPCET, CHU La Timone, AP-HM, UMR CNRS-Universite de la MediterraneeMarseilleFrance
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology Universitat de Barcelona and IDIBAPSBarcelonaSpain
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | | | - Pierre Payoux
- Université de ToulouseToulouseFrance
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | | | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | - Paolo Maria Rossini
- Catholic University, Policlinic GemelliRomeItaly
- IRCCS S. Raffaele PisanaRomeItaly
| | | | - Diego Albani
- IRCCS, Istituto di Ricerche FarmacologicheMilanItaly
| | | | - Regis Bordet
- Department of Pharmacology University of Lille Nord de FranceLilleFrance
| | - Jill Richardson
- GSK, Neurosciences Therapeutic AreaUnited Kingdom
- GSK R&D, China-U.K.United Kingdom
| | | | - Giovanni B. Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
14
|
Rolandi E, Galluzzi S, Marizzoni M, Ferrari C, Nobili F, Ranjeva JP, Bartrés-Faz D, Fiedler U, Schönknech P, Payoux P, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Visser PJ, Albani D, Forloni G, Bordet R, Blin O, Frisoni GB. O2‐04‐01: Cognitive Composite Measures in Amnestic MCI by Different AMYLOID/TAU Pathology. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Elena Rolandi
- IRCCS Istituto Centro San Giovanni di Dio-FatebenefratelliBresciaItaly
| | - Samantha Galluzzi
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Jean-Philippe Ranjeva
- CIC-UPCET, CHU La Timone, AP-HM, UMR CNRS-Universite de la MediterraneeMarseilleFrance
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology Universitat de Barcelona and IDIBAPSBarcelonaSpain
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | | | - Pierre Payoux
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | | | - Diego Albani
- IRCCS, Istituto di Ricerche FarmacologicheMilanItaly
| | | | - Regis Bordet
- Department of Pharmacology University of Lille Nord de FranceLilleFrance
| | | | - Giovanni B. Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
15
|
Pievani M, Marizzoni M, Pini L, Jovicich J, Nobili F, Ranjeva JP, Bartrés-Faz D, Fiedler U, Schönknech P, Payoux P, Beltramello A, Caulo M, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Visser PJ, Albani D, Forloni G, Bordet R, Richardson J, Blin O, Frisoni GB. IC‐P‐122: Structural and Diffusion Tensor Imaging in MCI Subjects With Intermediate Risk of Alzheimer’s Disease Based on CSF Profile. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
| | - Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Lorenzo Pini
- Department of Molecular and Translational Medicine University of BresciaBresciaItaly
- Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Jean-Philippe Ranjeva
- CIC-UPCET, CHU La Timone, AP-HM, UMR CNRS-Universite de la MediterraneeMarseilleFrance
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology Universitat de Barcelona and IDIBAPSBarcelonaSpain
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | | | - Pierre Payoux
- Université de ToulouseToulouseFrance
- INSERM, Imagerie cérébrale et handicaps neurologiquesToulouseFrance
| | | | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | - Paolo Maria Rossini
- Catholic University, Policlinic GemelliRomeItaly
- IRCCS S. Raffaele PisanaRomeItaly
| | | | - Diego Albani
- IRCCS, Istituto di Ricerche FarmacologicheMilanItaly
| | | | - Regis Bordet
- Department of Pharmacology University of Lille Nord de FranceLilleFrance
| | - Jill Richardson
- GSK R&D, China-U.K.United Kingdom
- GSK, Neurosciences Therapeutic AreaUnited Kingdom
| | | | - Giovanni B. Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
16
|
Marizzoni M, Pievani M, Pini L, Jovicich J, Nobili F, Ranjeva JP, Bartrés-Faz D, Fiedler U, Schönknech P, Payoux P, Beltramello A, Caulo M, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Visser PJ, Albani D, Forloni G, Bordet R, Richardson J, Blin O, Frisoni GB. P3‐232: Association Between Brain MRI Diffusion Alterations and CSF Biomarkers in Amnestic MCI. Alzheimers Dement 2016. [DOI: 10.1016/j.jalz.2016.06.1894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Moira Marizzoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Lorenzo Pini
- Department of Molecular and Translational Medicine University of BresciaBresciaItaly
- Laboratory of Neuroimaging and Alzheimer’s Epidemiology IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Jean-Philippe Ranjeva
- CIC-UPCET, CHU La Timone, AP-HM, UMR CNRS-Universite de la MediterraneeMarseilleFrance
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology Universitat de Barcelona and IDIBAPSBarcelonaSpain
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | | | - Pierre Payoux
- Université de ToulouseToulouseFrance
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | | | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | - Paolo Maria Rossini
- Catholic University Policlinic GemelliRomeItaly
- IRCCS S. Raffaele PisanaRomeItaly
| | | | - Diego Albani
- IRCCS, Istituto di Ricerche Farmacologiche Mario NegriMilanItaly
| | | | - Regis Bordet
- Department of Pharmacology University of Lille Nord de FranceLilleFrance
| | - Jill Richardson
- GSK R&DChina-UKU.K.United Kingdom
- GSK, Neurosciences Therapeutic AreaU.K. United Kingdom
| | | | - Giovanni B. Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
17
|
Galluzzi S, Marizzoni M, Babiloni C, Albani D, Antelmi L, Bagnoli C, Bartres-Faz D, Cordone S, Didic M, Farotti L, Fiedler U, Forloni G, Girtler N, Hensch T, Jovicich J, Leeuwis A, Marra C, Molinuevo JL, Nobili F, Pariente J, Parnetti L, Payoux P, Del Percio C, Ranjeva JP, Rolandi E, Rossini PM, Schönknecht P, Soricelli A, Tsolaki M, Visser PJ, Wiltfang J, Richardson JC, Bordet R, Blin O, Frisoni GB. Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a 'European ADNI study'. J Intern Med 2016; 279:576-91. [PMID: 26940242 DOI: 10.1111/joim.12482] [Citation(s) in RCA: 58] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND In the field of Alzheimer's disease (AD), the validation of biomarkers for early AD diagnosis and for use as a surrogate outcome in AD clinical trials is of considerable research interest. OBJECTIVE To characterize the clinical profile and genetic, neuroimaging and neurophysiological biomarkers of prodromal AD in amnestic mild cognitive impairment (aMCI) patients enrolled in the IMI WP5 PharmaCog (also referred to as the European ADNI study). METHODS A total of 147 aMCI patients were enrolled in 13 European memory clinics. Patients underwent clinical and neuropsychological evaluation, magnetic resonance imaging (MRI), electroencephalography (EEG) and lumbar puncture to assess the levels of amyloid β peptide 1-42 (Aβ42), tau and p-tau, and blood samples were collected. Genetic (APOE), neuroimaging (3T morphometry and diffusion MRI) and EEG (with resting-state and auditory oddball event-related potential (AO-ERP) paradigm) biomarkers were evaluated. RESULTS Prodromal AD was found in 55 aMCI patients defined by low Aβ42 in the cerebrospinal fluid (Aβ positive). Compared to the aMCI group with high Aβ42 levels (Aβ negative), Aβ positive patients showed poorer visual (P = 0.001), spatial recognition (P < 0.0005) and working (P = 0.024) memory, as well as a higher frequency of APOE4 (P < 0.0005), lower hippocampal volume (P = 0.04), reduced thickness of the parietal cortex (P < 0.009) and structural connectivity of the corpus callosum (P < 0.05), higher amplitude of delta rhythms at rest (P = 0.03) and lower amplitude of posterior cingulate sources of AO-ERP (P = 0.03). CONCLUSION These results suggest that, in aMCI patients, prodromal AD is characterized by a distinctive cognitive profile and genetic, neuroimaging and neurophysiological biomarkers. Longitudinal assessment will help to identify the role of these biomarkers in AD progression.
Collapse
Affiliation(s)
- S Galluzzi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - M Marizzoni
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - C Babiloni
- Department of Physiology and Pharmacology, University of Rome 'La Sapienza', Rome, Italy.,IRCCS San Raffaele Pisana of Rome, Rome, Italy
| | - D Albani
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - L Antelmi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - C Bagnoli
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - D Bartres-Faz
- Department of Psychiatry and Clinical Psychobiology, Faculty of Medicine, University of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain
| | - S Cordone
- Department of Physiology and Pharmacology, University of Rome 'La Sapienza', Rome, Italy
| | - M Didic
- Aix-Marseille Université, INSERM, Marseille, France.,Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
| | - L Farotti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - U Fiedler
- Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany
| | - G Forloni
- Department of Neuroscience, Mario Negri Institute for Pharmacological Research, Milan, Italy
| | - N Girtler
- Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy
| | - T Hensch
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - J Jovicich
- Center for Mind/Brain Sciences, University of Trento, Trento, Italy
| | - A Leeuwis
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands
| | - C Marra
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy
| | - J L Molinuevo
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, and IDIBAPS, Barcelona, Catalunya, Spain
| | - F Nobili
- Clinical Neurology, Department of Neurosciences, Rehabilitation, Ophthalmology and Maternal-Fetal Medicine, University of Genoa, Genoa, Italy
| | - J Pariente
- INSERM, Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France
| | - L Parnetti
- Clinica Neurologica, Università di Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy
| | - P Payoux
- INSERM, Imagerie Cérébrale et Handicaps Neurologiques, Toulouse, France
| | - C Del Percio
- SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy
| | - J-P Ranjeva
- Aix-Marseille Université, INSERM, Marseille, France.,Service de Neurologie et Neuropsychologie, APHM Hôpital Timone Adultes, Marseille, France
| | - E Rolandi
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy
| | - P M Rossini
- Department of Gerontology, Neurosciences & Orthopedics, Catholic University, Rome, Italy
| | - P Schönknecht
- Department of Psychiatry and Psychotherapy, University of Leipzig, Leipzig, Germany
| | - A Soricelli
- SDN Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy
| | - M Tsolaki
- Third Neurologic Clinic, Medical School, G. Papanikolaou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - P J Visser
- Department of Neurology, Alzheimer Centre, VU Medical Centre, Amsterdam, the Netherlands
| | - J Wiltfang
- Department of Psychiatry and Psychotherapy, Faculty of Medicine, LVR-Hospital Essen, University of Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center, Georg-August-University, Goettingen, Germany
| | - J C Richardson
- Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK
| | - R Bordet
- University of Lille, Inserm, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - O Blin
- Mediterranean Institute of Cognitive Neurosciences, Aix Marseille University, Marseille, France
| | - G B Frisoni
- Laboratory of Alzheimer's Neuroimaging & Epidemiology, Saint John of God Clinical Research Centre, Brescia, Italy.,Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | | |
Collapse
|
18
|
Marchitelli R, Minati L, Marizzoni M, Bosch B, Bartrés-Faz D, Müller BW, Wiltfang J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Schönknecht P, Hensch T, Hoffmann KT, Kuijer JP, Visser PJ, Barkhof F, Frisoni GB, Jovicich J. Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Hum Brain Mapp 2016; 37:2114-32. [PMID: 26990928 DOI: 10.1002/hbm.23157] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2015] [Revised: 02/16/2016] [Accepted: 02/17/2016] [Indexed: 12/31/2022] Open
Abstract
Understanding how to reduce the influence of physiological noise in resting state fMRI data is important for the interpretation of functional brain connectivity. Limited data is currently available to assess the performance of physiological noise correction techniques, in particular when evaluating longitudinal changes in the default mode network (DMN) of healthy elderly participants. In this 3T harmonized multisite fMRI study, we investigated how different retrospective physiological noise correction (rPNC) methods influence the within-site test-retest reliability and the across-site reproducibility consistency of DMN-derived measurements across 13 MRI sites. Elderly participants were scanned twice at least a week apart (five participants per site). The rPNC methods were: none (NPC), Tissue-based regression, PESTICA and FSL-FIX. The DMN at the single subject level was robustly identified using ICA methods in all rPNC conditions. The methods significantly affected the mean z-scores and, albeit less markedly, the cluster-size in the DMN; in particular, FSL-FIX tended to increase the DMN z-scores compared to others. Within-site test-retest reliability was consistent across sites, with no differences across rPNC methods. The absolute percent errors were in the range of 5-11% for DMN z-scores and cluster-size reliability. DMN pattern overlap was in the range 60-65%. In particular, no rPNC method showed a significant reliability improvement relative to NPC. However, FSL-FIX and Tissue-based physiological correction methods showed both similar and significant improvements of reproducibility consistency across the consortium (ICC = 0.67) for the DMN z-scores relative to NPC. Overall these findings support the use of rPNC methods like tissue-based or FSL-FIX to characterize multisite longitudinal changes of intrinsic functional connectivity. Hum Brain Mapp 37:2114-2132, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Rocco Marchitelli
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| | - Ludovico Minati
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy.,Scientific Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
| | - Moira Marizzoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni Di Dio-FBF, Brescia, Italy
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology, Hospital Clínic, and IDIBAPS, Barcelona, Spain
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat De Barcelona and IDIBAPS, Barcelona, Spain
| | - Bernhard W Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jens Wiltfang
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany.,Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg August University, Göttingen, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Luca Roccatagliata
- Department of Neuroradiology, IRCSS San Martino University Hospital and IST, Genoa, Italy.,Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Flavio Nobili
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Oliver Blin
- Pharmacology, Assistance Publique - Hôpitaux De Marseille, Aix-Marseille University-CNRS, UMR, Marseille, 7289, France
| | - Stephanie Bombois
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Renaud Lopes
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Régis Bordet
- University of Lille, INSERM, CHU Lille, U1171 - Degenerative and Vascular Cognitive Disorders, Lille, France
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix Marseille Université-CNRS, Marseille, France
| | | | - Mira Didic
- APHM, CHU Timone, Service De Neurologie Et Neuropsychologie, Marseille, France.,Aix-Marseille Université, INSERM INS UMR_S 1106, Marseille, 13005, France
| | - Hélène Gros-Dagnac
- INSERM, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, Toulouse, France.,Université De Toulouse, UPS, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, CHU Purpan, Place Du Dr Baylac, Toulouse Cedex 9, France
| | - Pierre Payoux
- INSERM, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, Toulouse, France.,Université De Toulouse, UPS, Imagerie Cérébrale Et Handicaps Neurologiques, UMR 825, CHU Purpan, Place Du Dr Baylac, Toulouse Cedex 9, France
| | | | | | | | - Núria Bargalló
- Department of Neuroradiology and Magnetic Resonace Image Core Facility, Hospital Clínic De Barcelona, IDIBAPS, Barcelona, Spain
| | - Antonio Ferretti
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Massimo Caulo
- Department of Neuroscience Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy.,Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | | | | | - Andrea Soricelli
- IRCCS SDN, Naples, Italy.,University of Naples Parthenope, Naples, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | | | - Piero Floridi
- Perugia General Hospital, Neuroradiology Unit, Perugia, Italy
| | - Magda Tsolaki
- 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece.,Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Paolo Maria Rossini
- Department of Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy.,IRCSS S.Raffaele Pisana, Rome, Italy
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | - Peter Schönknecht
- Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany
| | - Tilman Hensch
- Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany
| | | | - Joost P Kuijer
- Department of Physics and Medical Technology, VU University Medical Center, Amsterdam, the Netherlands
| | - Pieter Jelle Visser
- Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands.,Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands
| | - Frederik Barkhof
- Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, the Netherlands
| | - Giovanni B Frisoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine-IRCCS San Giovanni Di Dio-FBF, Brescia, Italy.,Memory Clinic and LANVIE, Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| |
Collapse
|
19
|
Marizzoni M, Ferrari C, Galluzzi S, Visser P, Parnetti L, Nobili F, Didic M, Bartrés-Faz D, Fiedler U, Schonknecht P, Payoux P, Soricelli A, Tsolaki M, Rossini P, Forloni G, Bordet R, Blin O, Frisoni G. Baseline CSF Aβ, Aβ/T-TAU and Aβ/P-tau distributions to classify pharmacog MCI patients. Neurobiol Aging 2016. [DOI: 10.1016/j.neurobiolaging.2016.01.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
20
|
Marizzoni M, Jovicich J, Nobili F, Didic M, Bartres D, Fiedler U, Schönknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Forloni G, Bordet R, Blin O, Frisoni GB. P3‐182: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.1553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/ IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schönknecht
- LIFE–Leipzig Research Center for Civilization DiseasesLeipzigGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - Philip Scheltens
- VU University Medical CenterAmsterdamNetherlands
- Neuroscience Campus AmsterdamAmsterdamNetherlands
| | | | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE-Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
21
|
Marizzoni M, Jovicich J, Nobili F, Didic M, Bartres D, Fiedler U, Schönknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Forloni G, Bordet R, Blin O, Frisoni GB. IC‐P‐115: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E‐ADNI study: Preliminary data. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/ IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schönknecht
- LIFE – Leipzig Research Center for Civilization DiseasesLeipzigGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipziGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - Philip Scheltens
- VU University Medical CenterAmsterdamNetherlands
- Neuroscience Campus AmsterdamAmsterdamNetherlands
| | | | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
22
|
Jovicich J, Marizzoni M, Minati L, Nobili F, Didic M, Bartres D, Fiedler U, Schonknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens NM, Forloni G, Bordet R, Blin O, Frisoni GB. IC‐P‐137: Longitudinal reproducibility of default‐mode network connectivity in healthy elderly participants: A multicentric resting‐state fMRI study. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
| | - Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/ IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Ludovico Minati
- Fondazione IRCCS Istituto Neurologico Carlo BestaMilanItaly
- Center for Mind/Brain SciencesUniversity of TrentoMattarelloItaly
| | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schonknecht
- Department of NeuroradiologyUniversity Hospital LeipzigLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | - Alberto Beltramello
- Direttore Neuroradiologia e DAI Patologia e Diagnostica Azienda Ospedaliera Universitaria Integrata VeronaVeronaItaly
| | | | | | | | | | | | | | - Regis Bordet
- Service de Pharmacologie‐Hôpital Huriez‐CHRULilleFrance
| | - Olivier Blin
- Mediterranean Institute of Cognitive NeurosciencesMarseilleFrance
| | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
23
|
Marizzoni M, Nobili F, Didic M, Bartres D, Fiedler U, Schönknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Bordet R, Blin O, Frisoni GB, Jovicich J. IC‐04‐05: Multisite hippocampal subfields reproducibility: A european 3T study. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schönknecht
- LIFE – Leipzig Research Center for Civilization DiseasesLeipzigGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - Philip Scheltens
- VU University Medical CenterAmsterdamNetherlands
- Neuroscience Campus AmsterdamAmsterdamNetherlands
| | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | | | |
Collapse
|
24
|
Marizzoni M, Jovicich J, Nobili F, Didic M, Bartres D, Fiedler U, Schonknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Forloni G, Bordet R, Blin O, Frisoni GB. P4‐087: Longitudinal white matter alterations of MCI patients in WP5 PharmaCog/E‐ADNI study: Preliminary data. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.1792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of Epidemiology, Neuroimaging and TelemedicineIRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and ClinicsUniversity Duisburg-EssenEssenGermany
| | - Peter Schonknecht
- Department of NeuroradiologyUniversity Hospital LeipzigLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | | | | | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University HospitalsUniversity of GenevaGenevaSwitzerland
| | | |
Collapse
|
25
|
Marizzoni M, Nobili F, Didic M, Bartres D, Fiedler U, Schönknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Bordet R, Blin O, Frisoni GB, Jovicich J. P2‐174: Multi‐site hippocampal subfields reproducibility: A european 3T study. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/ IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schönknecht
- LIFE – Leipzig Research Center for Civilization DiseasesLeipzigGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital LeipzigLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - Philip Scheltens
- VU University Medical CenterAmsterdamNetherlands
- Neuroscience Campus AmsterdamAmsterdamNetherlands
| | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | | | |
Collapse
|
26
|
Marizzoni M, Jovicich J, Nobili F, Didic M, Bartres D, Fiedler U, Schönknecht P, Payoux P, Beltramello A, Soricelli A, Parnetti L, Tsolaki M, Rossini PM, Scheltens P, Forloni G, Bordet R, Blin O, Frisoni GB. IC‐P‐116: Hippocampal subfield changes in mild cognitive impairment patients with Alzheimer's disease pathology. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Moira Marizzoni
- Laboratory of EpidemiologyNeuroimaging and Telemedicine/ IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | | | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
- Aix‐Marseille UniversitéMarseilleFrance
| | | | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Peter Schönknecht
- LIFE – Leipzig Research Center for Civilization DiseasesLeipzigGermany
- Department of Psychiatry and PsychotherapyUniversity Hospital Leipzig, GermanyLeipzigGermany
| | - Pierre Payoux
- Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
- Université de ToulouseToulouseFrance
| | | | | | | | - Magda Tsolaki
- Aristotle University of ThessalonikiThessalonikiGreece
| | | | - Philip Scheltens
- VU University Medical CenterAmsterdamNetherlands
- Neuroscience Campus AmsterdamAmsterdamNetherlands
| | | | | | | | - Giovanni Battista Frisoni
- IRCCS Istituto Centro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of AgingUniversity Hospitals and University of GenevaGenevaSwitzerland
| | | |
Collapse
|
27
|
Marizzoni M, Antelmi L, Bosch B, Bartrés-Faz D, Müller BW, Wiltfang J, Fiedler U, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Zoccatelli G, Alessandrini F, Beltramello A, Bargalló N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Salvadori N, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinidis M, Drevelegas A, Rossini PM, Marra C, Hoffmann KT, Hensch T, Schönknecht P, Kuijer JP, Visser PJ, Barkhof F, Bordet R, Frisoni GB, Jovicich J. Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. Hum Brain Mapp 2015; 36:3516-27. [PMID: 26043939 DOI: 10.1002/hbm.22859] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Revised: 04/28/2015] [Accepted: 05/16/2015] [Indexed: 12/20/2022] Open
Abstract
Recently, there has been an increased interest in the use of automatically segmented subfields of the human hippocampal formation derived from magnetic resonance imaging (MRI). However, little is known about the test-retest reproducibility of such measures, particularly in the context of multisite studies. Here, we report the reproducibility of automated Freesurfer hippocampal subfields segmentations in 65 healthy elderly enrolled in a consortium of 13 3T MRI sites (five subjects per site). Participants were scanned in two sessions (test and retest) at least one week apart. Each session included two anatomical 3D T1 MRI acquisitions harmonized in the consortium. We evaluated the test-retest reproducibility of subfields segmentation (i) to assess the effects of averaging two within-session T1 images and (ii) to compare subfields with whole hippocampus volume and spatial reliability. We found that within-session averaging of two T1 images significantly improved the reproducibility of all hippocampal subfields but not that of the whole hippocampus. Volumetric and spatial reproducibility across MRI sites were very good for the whole hippocampus, CA2-3, CA4-dentate gyrus (DG), subiculum (reproducibility error∼2% and DICE > 0.90), good for CA1 and presubiculum (reproducibility error ∼ 5% and DICE ∼ 0.90), and poorer for fimbria and hippocampal fissure (reproducibility error ∼ 15% and DICE < 0.80). Spearman's correlations confirmed that test-retest reproducibility improved with volume size. Despite considerable differences of MRI scanner configurations, we found consistent hippocampal subfields volumes estimation. CA2-3, CA4-DG, and sub-CA1 (subiculum, presubiculum, and CA1 pooled together) gave test-retest reproducibility similar to the whole hippocampus. Our findings suggest that the larger hippocampal subfields volume may be reliable longitudinal markers in multisite studies.
Collapse
Affiliation(s)
- Moira Marizzoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS San Giovanni Di Dio-FBF, Brescia, Italy
| | - Luigi Antelmi
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Beatriz Bosch
- Department of Psychiatry and Clinical Psychobiology, Universitat De Barcelona and IDIBAPS, Barcelona, Spain
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical Psychobiology, Universitat De Barcelona and IDIBAPS, Barcelona, Spain
| | - Bernhard W Müller
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Jens Wiltfang
- Department of Psychiatry and Psychotherapy, University Medical Center (UMG), Georg-August University, Göttingen, Germany
| | - Ute Fiedler
- LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany
| | - Luca Roccatagliata
- Department of Neuroradiology, IRCSS San Martino University Hospital and IST, Genoa, Italy
- Department of Health Sciences, University of Genoa, Genoa, Italy
| | - Agnese Picco
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Flavio Nobili
- Department of Neuroscience, Ophthalmology, Genetics and Mother-Child Health (DINOGMI), University of Genoa, Genoa, Italy
| | - Olivier Blin
- Pharmacology, Assistance Publique - Hôpitaux De Marseille, Aix-Marseille University - CNRS, UMR 7289, Marseille, France
| | - Stephanie Bombois
- Department of Neurology, INSERM U1171, Lille University, Lille, France
| | - Renaud Lopes
- Department of Neuroradiology, INSERM U1171, Lille University, Lille, France
| | - Julien Sein
- CRMBM-CEMEREM, UMR 7339, Aix Marseille Université - CNRS, Marseille, France
| | | | - Mira Didic
- Service de Neurologie et Neuropsychologie, APHM, CHU Timone, Marseille, France
- Aix-Marseille Université, Inserm, INS UMR_S 1106, 13005, Marseille, France
| | - Hélène Gros-Dagnac
- Imagerie Cérébrale Et Handicaps Neurologiques, INSERM, Toulouse, F, 31024, France
- Université Toulouse 3 Paul Sabatier, UMR 825 Imagerie Cérébrale Et Handicaps Neurologiques, Toulouse, F, 31024, France
| | - Pierre Payoux
- Imagerie Cérébrale Et Handicaps Neurologiques, INSERM, Toulouse, F, 31024, France
- Université Toulouse 3 Paul Sabatier, UMR 825 Imagerie Cérébrale Et Handicaps Neurologiques, Toulouse, F, 31024, France
| | - Giada Zoccatelli
- Service of Neuroradiology, University Hospital of Verona, Verona, Italy
| | | | | | - Núria Bargalló
- Department of Neuroradiology and Magnetic Resonace Image Core Facility, Hospital Clínic De Barcelona, IDIBAPS, Barcelona, Spain
| | - Antonio Ferretti
- Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy
- Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | - Massimo Caulo
- Department of Neuroscience, Imaging and Clinical Sciences, University "G. d'Annunzio" of Chieti, Italy
- Institute for Advanced Biomedical Technologies (ITAB), University "G. d'Annunzio" of Chieti, Italy
| | | | | | - Andrea Soricelli
- IRCCS SDN, Naples, Italy
- University of Naples Parthenope, Naples, Italy
| | - Nicola Salvadori
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | - Lucilla Parnetti
- Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy
| | | | - Piero Floridi
- Neuroradiology Unit, Perugia General Hospital, Perugia, Italy
| | - Magda Tsolaki
- 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | | | - Antonios Drevelegas
- Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece
- Department of Radiology, Aristotle University of Thessaloniki, Thessaloniki, Greece
| | - Paolo Maria Rossini
- Deptartment of Geriatrics, Neuroscience and Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy
- IRCSS S.Raffaele Pisana, Rome, Italy
| | - Camillo Marra
- Center for Neuropsychological Research, Catholic University, Rome, Italy
| | | | - Tilman Hensch
- Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany
| | - Peter Schönknecht
- Department of Psychiatry and Psychotherapy, University Hospital Leipzig, Leipzig, Germany
| | - Joost P Kuijer
- Deptartment of Physics and Medical Technology, VU University Medical Center, Amsterdam, the Netherlands
| | - Pieter Jelle Visser
- Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands
| | - Frederik Barkhof
- Radiology and Image Analysis Centre (IAC), VU University Medical Center, Amsterdam, the Netherlands
| | - Régis Bordet
- Department of Pharmacology, INSERM U1171, Lille University, Lille, France
| | - Giovanni B Frisoni
- LENITEM Laboratory of Epidemiology, Neuroimaging, & Telemedicine - IRCCS San Giovanni Di Dio-FBF, Brescia, Italy
- Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Jorge Jovicich
- Center for Mind/Brain Sciences (CIMEC), University of Trento, Rovereto, Italy
| |
Collapse
|
28
|
Jung S, Selzer S, Loβner C, Kuhn K, Fiedler U, KlotzbUcher A, Zucht H, Koncarevic S, Prinz T, Hertfelder D, Boehme K, Volkmer H, Kubbutat M, Budde P, Pike I. 331 Biomarker discovery and validation for assessing the response to cMet inhibition and functional inactivation. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70457-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Dolado I, Fiedler U, Strobel H, Metz C, Stumpp MT, Rojkjaer L. Abstract P4-12-30: A bivalent Her2 targeting DARPin with high efficacy against Her2-low and Her2-positive tumors. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-12-30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The approval of Herceptin, Perjeta and Kadcyla has dramatically improved the outcome of the 15% of breast cancer patients with high expression of Her2 (Her2-positive, IHC3+). In contrast, up to 50% of women with breast cancer express low levels of Her2 (Her2-low, IHC+2 or +1) at diagnosis, and these patients do not derive benefit from approved Her2 targeted therapies. It is estimated that 5-10% of Her2-positive patients will also develop Her2-low metastases refractory to treatment. Therefore, new therapeutic strategies are needed to alleviate the high tumor burden of Her2-low patients.
We generated a bivalent Designed Ankyrin Repeat Protein (DARPin) containing two anti-Her2 moieties that target unique non-overlapping epitopes on Her2 (biparatopic). The biparatopic DARPin exerts a strong pro-apoptotic response on a panel of breast and gastric cancer cell lines, which cannot be fully recapitulated by treatment with Herceptin, Perjeta or both combined. DARPin treatment of Her2-positive breast cancer BT474 cells induces apoptosis (IC50 < 1nM) in virtually all cells within 24 hours, whereas single or combined treatment with Herceptin and/or Perjeta reduces proliferation by 50% (IC50 = 2-4nM). The biparatopic DARPin inhibits as well the viability (via apoptosis) of Her2-low MDAMB175 cells with a 100-fold higher potency than Herceptin. Mechanistically, treatment with the anti-Her2 biparatopic DARPin inhibits both Her2 and Her3 signaling, which in turn results in the induction of apoptosis. Interestingly, cell treatment with the mix of the two individual anti-Her2 DARPin moieties does not recapitulate the apoptotic effect of the biparatopic molecule, indicating that both moieties must be linked for maximum efficacy. In vivo, the biparatopic DARPin shows efficient anti-tumor activity in established breast cancer Her2-positive xenografts and Her2-low PDX tumor models. DARPin treatment of Her2-positive BT474 xenograft in BALB/c mice results in rapid tumor regression (50% tumor shrinkage after one dose) that is sustained at least during one month after the last dose. The biparatopic DARPin strongly inhibits tumor growth as well in a Her2-low breast cancer PDX in NMRI mice, where it demonstrates superior efficacy compared to Herceptin (DARPin/Herceptin tumor volume ratio < 30%).
In summary, biparatopic targeting of Her2 enables inhibition of both Her2 and Her3, and blocks a tumor driver and its resistance mechanism. As a result, the DARPin interferes with both the proliferation and survival of tumor cells and triggers durable anti-tumor responses in vivo. DARPin treatment of Her2 positive tumors in mice show equivalent efficacy to Herceptin with faster kinetics; an effect that is magnified in Her2-low PDX tumors where the DARPin provides superior tumor control to Herceptin. Altogether, our data demonstrate the potential for the biparatopic DARPin to surpass some of the limitations of approved Her2 targeted agents, and warrants clinical investigation.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-30.
Collapse
Affiliation(s)
- I Dolado
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| | - U Fiedler
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| | - H Strobel
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| | - C Metz
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| | - MT Stumpp
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| | - L Rojkjaer
- Molecular Partners AG, Schlieren, Zulia, Switzerland
| |
Collapse
|
30
|
Faber J, Berkhout M, Fiedler U, Avlar M, Witteman B, Vos A, Henke M, Garssen J, van Helvoort A, Otten M, Arends J. Rapid EPA and DHA incorporation and reduced PGE2 levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial. Clin Nutr 2013; 32:338-45. [DOI: 10.1016/j.clnu.2012.09.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Revised: 06/14/2012] [Accepted: 09/19/2012] [Indexed: 02/03/2023]
|
31
|
Abstract
Due to the demographic developments, diagnosis and treatment, dementia constitutes an increasing medical challenge and is likely to have an increasing socioeconomic impact. Dementia does not reflect a single disease but encompasses a variety of underlying conditions, heterogeneous clinical courses and therapeutic approaches, among which Alzheimer's disease represents the most common cause. Therefore, a thorough differential diagnosis of dementia is of major importance. To date the current diagnosis of dementia according to ICD-10/DMS-IV is based on clinical criteria. In addition, the concept of mild cognitive impairment comprises early cognitive dysfunction without clinically apparent dementia. Alzheimer's disease is more and more conceptualized as a disease continuum with mild cognitive impairment as an early and manifest dementia as the later stage of the disease. This review gives an overview on the current diagnostic approaches and the proposed revisions of diagnostic and research criteria for Alzheimer's disease.
Collapse
Affiliation(s)
- U Fiedler
- Gerontopsychiatrisches Zentrum, LVR-Klinikum Essen, Kliniken und Institut der Universität Duisburg Essen, Wickenburgstr. 23, 45147 Essen, Deutschland
| | | | | | | |
Collapse
|
32
|
Fasol U, Frost A, Büchert M, Arends J, Fiedler U, Scharr D, Scheuenpflug J, Mross K. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann Oncol 2011; 23:1030-6. [PMID: 21693769 DOI: 10.1093/annonc/mdr300] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND EndoTAG-1 (ET), a novel formulation of cationic liposomes carrying embedded paclitaxel (Taxol), shows antitumoral activity, targeting tumor endothelial cells in solid tumors. Patients with advanced metastatic cancer were evaluated investigating effects on pharmacokinetics and tumor vasculature using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and contrast-enhanced ultrasound (CEUS). PATIENTS AND METHODS The pharmacokinetic (PK) profile of ET (22 mg/m(2) i.v.) was evaluated after single and repeated doses. DCE-MRI and CEUS explored hepatic metastases before, during and after the 4-week treatment cycle. Angiogenic biomarkers were assessed. Tumor response was evaluated by modified RECIST. RESULTS The PK profile demonstrated slight accumulation of paclitaxel after repeated doses. DCE-MRI parameters K(trans) and/or iAUC(60) showed a trend to decrease. Changes of blood flow-dependent parameters of DCE-MRI and CEUS were well correlated. Angiogenic biomarkers revealed no clear trend. ET was generally well tolerated; common toxic effects were fatigue and hypersensitivity reactions. Nine (9 of 18) patients had stable disease after the first treatment cycle. Four patients without disease progression continued treatment. CONCLUSIONS This study including multiple pretreated patients with different metastatic cancer revealed individually distinctive hemodynamic alterations by DCE-MRI. The PK profiles of ET were similar as observed previously.
Collapse
Affiliation(s)
- U Fasol
- Magnetic Resonance Development and Application Center, Department of Radiology, University Medical Center Freiburg, Freiburg, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Graeser R, Birkle M, Obododzie-Schäfer C, Esser N, Fiedler U, Schaechtele C. 643 Phosphorylated histone H3 and S6 proteins as biomarkers for targeted anti-cancer drug action measured using a combined IHC/Western method in skin biopsies. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)72350-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
34
|
Abstract
Hyperprolactinemia is a frequent side-effect in the use of atypical antipsychotics. The propensity to induce hyperprolactinemia is highly substance dependent and hyperprolactinemia is not always associated with clinical side-effects. We report a case in which hyperprolactinemia and amenorrhea under the treatment with olanzapine gets normalized after the addition of aripiprazole.
Collapse
Affiliation(s)
- J Wolf
- Department of Psychiatry, Charité-Campus Benjamin Franklin, University Medicine Berlin, Berlin, Germany.
| | | |
Collapse
|
35
|
|
36
|
Wolf J, Fiedler U, Anghelescu I, Schwertfeger N. Manic switch in a patient with treatment-resistant bipolar depression treated with modafinil. J Clin Psychiatry 2006; 67:1817. [PMID: 17196066 DOI: 10.4088/jcp.v67n1122a] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
37
|
Ribaldi F, Jovicich J, Ferrari C, Bosch B, Bartrés-Faz D, Müller BW, Wiltfang J, Fiedler U, Montalti M, Roccatagliata L, Picco A, Nobili F, Blin O, Bombois S, Lopes R, Bordet R, Sein J, Ranjeva JP, Didic M, Gros-Dagnac H, Payoux P, Alessandrini F, Beltramello A, Bargallo N, Ferretti A, Caulo M, Aiello M, Cavaliere C, Soricelli A, Parnetti L, Tarducci R, Floridi P, Tsolaki M, Constantinides M, Drevelegas A, Rossini P, Marra C, Schonknecht P, Hensch T, Hoffmann KT, Kuijer J, Visser PJ, Barkhof F, Frisoni GB, Marizzoni M. IC‐P‐126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION. Alzheimers Dement 2006. [DOI: 10.1016/j.jalz.2018.06.2192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Federica Ribaldi
- University of BresciaBresciaItaly
- Istituto di Ricovero e Cura a Carattere ScientificoCentro San Giovanni di Dio FatebenefratelliBresciaItaly
| | | | - Clarissa Ferrari
- Istituto di Ricovero e Cura a Carattere ScientificoCentro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Beatriz Bosch
- Alzheimer's Disease and Other Cognitive Disorders Unit, Hospital ClínicInstitut d'Investigacions Biomediques August Pi i SunyerBarcelonaSpain
| | - David Bartrés-Faz
- Department of Psychiatry and Clinical PsychobiologyUniversitat de Barcelona, August Pi i Sunyer Biomedical Research InstituteBarcelonaSpain
| | | | - Jens Wiltfang
- Department of Psychiatry and PsychotherapyUniversity Medical CenterGoettingenGermany
| | - Ute Fiedler
- Institutes and Clinics of the University Duisburg-EssenEssenGermany
| | - Martina Montalti
- Istituto di Ricovero e Cura a Carattere ScientificoCentro San Giovanni di Dio FatebenefratelliBresciaItaly
| | - Luca Roccatagliata
- Department of NeuroscienceOphthalmology and Genetics University of GenoaGenoaItaly
| | - Agnese Picco
- Neurology Unit, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria, San MartinoUniversity of GenoaGenoaItaly
| | | | - Olivier Blin
- Aix-Marseille University-Centre National de la Recherche ScientifiqueMarseilleFrance
| | | | - Renaud Lopes
- INSERM, Neuroradiology DepartmentUniversity HospitalLilleFrance
| | - Régis Bordet
- Service de Pharmacologie-Hôpital Huriez- Centre Hospitalier Régional UniversitaireLilleFrance
| | - Julien Sein
- Centre de Résonance Magnétique Biologique et Médicale‐Centre d'Exploration Métabolique par Résonance MagnétiqueAix Marseille UniversityMarseilleFrance
| | - Jean-Philippe Ranjeva
- Centre Investigation Clinique ‐ Unité de Pharmacologie Clinique et d'Évaluations Thérapeutiques, Centre Hospitalier Universitaire, La Timone, Assistance Publique ‐ Hopitaux de MarseilleCentre National de la Recherche Scientifique ‐Universite de la MediterraneeMarseilleFrance
| | - Mira Didic
- Service de Neurologie et NeuropsychologieMarseilleFrance
| | | | - Pierre Payoux
- INSERM, Imagerie Cérébrale et Handicaps NeurologiquesToulouseFrance
| | | | | | - Núria Bargallo
- Imaging Diagnostic Center Radiology DepartmentHospital Clínic i Provincial de BarcelonaBarcelonaSpain
| | - Antonio Ferretti
- Department of Neuroscience, Imaging and Clinical SciencesUniversity G. d'AnnunzioChietiItaly
| | | | - Marco Aiello
- Istituto di Ricovero e Cura a Carattere Scientifico, SDN Istituto di Ricerca Diagnostica e Nucleare SpANaplesItaly
| | - Carlo Cavaliere
- Istituto di Ricovero e Cura a Carattere Scientifico, SDN Istituto di Ricerca Diagnostica e Nucleare SpANaplesItaly
| | - Andrea Soricelli
- IR SDN per la Ricerca e l'Alta Formazione in Diagnostica NucleareNaplesItaly
| | | | | | - Piero Floridi
- Perugia General HospitalNeuroradiology UnitPerugiaItaly
| | - Magda Tsolaki
- First Department of NeurologyAHEPA University Hospital, MakedoniaThessalonikiGreece
| | | | | | - Paolo Rossini
- Department of Gerontology, Neurosciences and OrthopedicsCatholic UniversityRomeItaly
| | | | - Peter Schonknecht
- LIFE, Leipzig Research Center for Civilization DiseasesLeipzigGermany
| | | | | | - Joost Kuijer
- VU University Medical CenterAmsterdamNetherlands
| | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Amsterdam NeuroscienceVU University Medical CenterAmsterdamNetherlands
| | - Frederik Barkhof
- Institutes of Neurology and Healthcare EngineeringUniversity CollegeLondonUnited Kingdom
| | - Giovanni B. Frisoni
- Istituto di Ricovero e Cura a Carattere ScientificoCentro San Giovanni di Dio FatebenefratelliBresciaItaly
- Memory Clinic and Laboratory of Neuroimaging of AgingGenevaSwitzerland
| | - Moira Marizzoni
- Istituto di Ricovero e Cura a Carattere ScientificoCentro San Giovanni di Dio FatebenefratelliBresciaItaly
| |
Collapse
|
38
|
Klein JP, Fiedler U, Appel H, Quante A, Jockers-Scherübl MC. Massive creatine kinase elevations with quetiapine: report of two cases. Pharmacopsychiatry 2006; 39:39-40. [PMID: 16453254 DOI: 10.1055/s-2006-931478] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Massive elevations of serum creatine kinase (CK) can occur in a significant number of patients treated with neuroleptics in the absence of neuroleptic malignant syndrome (NMS). We report two cases of CK-elevations associated with quetiapine treatment, which disappeared after drug discontinuation. To our knowledge, case number one is the first case of quetiapine-induced CK elevation in a neuroleptic-naïve patient. We thus suggest CK assessment when myalgia occurs with neuroleptic treatment.
Collapse
|
39
|
Fiedler E, Fiedler M, Proetzel G, Scheuermann T, Fiedler U, Rudolph R. Affilin™ Molecules. Food and Bioproducts Processing 2006. [DOI: 10.1205/fbp.05222] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
40
|
Schindler A, Fiedler U, Meye A, Schmidt U, Fussel S, Pilarsky C, Herrmann J, Wirth M. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int J Oncol 2001. [DOI: 10.3892/ijo.19.1.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
41
|
Schindler A, Fiedler U, Meye A, Schmidt U, Füssel S, Pilarsky C, Herrmann J, Wirth MP. Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int J Oncol 2001; 19:25-30. [PMID: 11408918] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
Abstract
Telomerase, a ribonucleoprotein complex is activated in the vast majority of human malignancies, including prostate cancer. Its inhibition is a putative way to affect cancer proliferation and might be used in the therapy of tumors. We analysed the influence of antisense phosphorothioate oligonucleotides (PTO) against the reverse transcriptase subunit of telomerase on prostate cancer cell viability, telomerase activity and telomere length. DU145 prostate cancer cells were cultivated in PTO containing medium. The PTO-incorporation was confirmed by confocal laser scanning microscopy. Cell viability was measured by a WST-1 tetrazolium assay. After 15 days of antisense PTO treatment, a significant inhibition of cell viability occurred. Telomerase activity was determined by a telomeric repeat amplification protocol (TRAP) assay and telomere length by Southern blot analysis. Since the long-term telomerase antisense treatment reduces the viability of prostate cancer cells significantly, this antisense approach could be a new therapeutic strategy to treat patients with advanced prostate cancer.
Collapse
Affiliation(s)
- A Schindler
- Department of Urology, Fetscherstrasse 74, Technical University of Dresden, Dresden, Germany
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Abstract
The RNA polymerase II (pol II) transcription complex undergoes a structural transition around registers 20-25, as indicated by ExoIII footprinting analyses. We have employed a highly purified system to prepare pol II complexes stalled at very precise positions during the initial stage of transcript elongation. Using potassium permanganate we analyzed the open region ('transcription bubble') of complexes stalled between registers 15 and 35. We found that from register 15 up to 25 the transcription bubble expands concomitantly with RNA synthesis. At registers 26 and 27 the bubble has a high tendency to retract at the leading edge. Addition of transcription elongation factor TFIIS re-extends the bubble to the stall site, resulting in complexes competent for transcript elongation. These findings are discussed in the light of the recently determined structures for RNA polymerases.
Collapse
Affiliation(s)
- U Fiedler
- Department of Physiological Chemistry, University Medical Center Utrecht, Stratenum Building, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands
| | | |
Collapse
|
43
|
Fiedler U, Ehlers W, Meye A, Füssel S, Faller G, Schmidt U, Wirth MP. LOH analyses in the region of the putative tumour suppressor gene C13 on chromosome 13q13. Anticancer Res 2001; 21:2341-50. [PMID: 11724291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
BACKGROUND In previous studies we isolated a new cDNA fragment named C13 which is down-regulated in malignant prostate tissues. The corresponding gene is localized on chromosome 13q13 between the known tumour suppressor genes (TSG) BRCA-2 and RB-1. MATERIALS AND METHODS Loss of heterozygosity (LOH) analyses were carried out in the region of C13 in order to investigate the importance of the new putative TSG for prostate cancer development. Using semiquantitative LOH analysis, we screened 21 prostate carcinoma patients of different tumour stages (pT2-pT4) for 14 microsatellite markers in the region of C13 (13q13) and in the flanking BRCA-2 and the RB-1 loci. RESULTS For 18 (86%) patients LOH or allelic imbalances were found. We identified three to nine alterations in affected tumours per marker. An overall genetic alteration frequency per patient of 38% (86 of 225 informative cases) could be calculated. One important finding regarding the overall frequency of determined microsatellite instability is that the LOH/AI rate of 47% for the seven C13-associated markers was higher than for the four markers of the RB-1 locus (39%) and for the three BRCA-2 markers (25%). Surprisingly, defining LOH critical regions (LCR) for the investigated marker panel, eight of the ten affected LCR cases showed chromosomal imbalances simultaneously for the RB-1 and the C13 LOH markers. CONCLUSIONS The high LOH rate for eight different microsatellite markers in and around the putative TSG locus C13 on chromosome 13q13 further supports an involvement of C13 in prostate tumourigenesis.
Collapse
Affiliation(s)
- U Fiedler
- Department of Urology, Technical University Dresden, University Erlangen, Germany
| | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
Although local prostate cancer (PC) can be cured in most cases by radical prostatectomy, therapies for metastatic and androgen-independent PC are limited and rather unsatisfactory. Gene and immunotherapy based on progress in molecular biology are novel treatment options especially for these PC stages. In the field of passive immunotherapy, chimeric/recombinant antibodies and derivatives thereof show promising results in early clinical trails (phase I/II). Before treatment, a careful selection of patients who could profit from this therapy is important (theranostics). Concerning active immunotherapy, administration of dendritic cells loaded with PC-specific tumor antigens seems to be an interesting therapy option. Promising gene therapeutic approaches include antisense and suicide gene therapy. Antisense therapy studies revealed the advantage that even systemic treatment does not lead to strong toxic side effects if the target gene is not involved in important cell functions. Improvement of the gene therapy vectors and identification of new therapeutic genes for PC are essential prerequisites for successful application in humans. Present developments of alternative approaches show that future treatments will be very patient specific.
Collapse
Affiliation(s)
- U Fiedler
- Klinik und Poliklinik für Urologie, Universitätsklinikum, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden
| | | |
Collapse
|
45
|
Schmidt U, Fiedler U, Pilarsky CP, Ehlers W, Füssel S, Haase M, Faller G, Sauter G, Wirth MP. Identification of a novel gene on chromosome 13 between BRCA-2 and RB-1. Prostate 2001; 47:91-101. [PMID: 11340631 DOI: 10.1002/pros.1051] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
METHODS AND RESULTS By differential display we isolated a new cDNA-fragment, named C13, that is downregulated in malignant prostate tissues. Northern hybridization revealed the fragment to be part of 3.0 and 4.4 kb mRNAs. Fluorescence in situ hybridization, Southern blotting and radiation hybrid mapping demonstrated a chromosomal localization of C13 on 13q12-14 closest to the SHGC-34125 marker. In the 5% chromosomal environment of C13 we detected changes of the allelic status in 13 of 21 prostate cancers. A downregulation was detected at the mRNA level in patients with advanced carcinoma. The 3.0 kb full length cDNA clone encodes a protein with an open reading frame of 2,202 bp or 733 amino acids. The corresponding protein contains a putative nuclear localization signal, several glutamine clusters and an alpha-helix-rich domain. By in situ RNA hybridization we could demonstrate the mainly epithelial expression of the C13 mRNA in prostatic tissue. CONCLUSIONS The localization of C13 between the tumor suppressor genes BRCA-2 and RB-1, the detected allelic imbalances, the downregulation of its mRNA in some prostatic cancer tissues, the epithelial expression and the described protein structure suggest that this gene encodes a protein that may have tumor or metastasis suppressing function in prostate tissue.
Collapse
MESH Headings
- BRCA2 Protein
- Chromosomes, Human, Pair 13/genetics
- DNA, Complementary/genetics
- DNA, Complementary/isolation & purification
- DNA, Complementary/metabolism
- DNA, Neoplasm/genetics
- DNA, Neoplasm/isolation & purification
- DNA, Neoplasm/metabolism
- Gene Expression Profiling
- Genes, Tumor Suppressor
- Humans
- In Situ Hybridization, Fluorescence
- Loss of Heterozygosity
- Male
- Neoplasm Proteins/chemistry
- Neoplasm Proteins/genetics
- Prostatic Neoplasms/chemistry
- Prostatic Neoplasms/genetics
- RNA, Messenger/biosynthesis
- RNA, Messenger/genetics
- RNA, Neoplasm/biosynthesis
- RNA, Neoplasm/genetics
- Radiation Hybrid Mapping
- Random Amplified Polymorphic DNA Technique
- Retinoblastoma Protein/chemistry
- Retinoblastoma Protein/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Transcription Factors/chemistry
- Transcription Factors/genetics
Collapse
Affiliation(s)
- U Schmidt
- Department of Urology, Technical University of Dresden, Dresden, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Abstract
The precise, sequence-specific regulation of RNA synthesis is the primary mechanism underlying differential gene expression. This general statement applies to both prokaryotic and eukaryotic organisms, as well as to their viral pathogens. Thus, it is not surprising that genomes use a substantial portion of their protein-coding content to regulate the process of RNA synthesis. Transcriptional regulation in bacterial systems is particularly well understood. In this essay, we build on this knowledge and propose two opposing models to describe promoter opening and transcription initiation in the eukaryotic RNA polymerase II system. Promoter opening in the "twisting by cranking" model is based on changes in the trajectory of DNA. In contrast, invasion of single-stranded DNA-binding proteins between the DNA strands drives the reaction in the "peeling by binding" model.
Collapse
Affiliation(s)
- U Fiedler
- Laboratory for Physiological Chemistry, Centre for Biomedical Genetics, Utrecht University, Utrecht, The Netherlands
| | | |
Collapse
|
47
|
Winkler GS, Araújo SJ, Fiedler U, Vermeulen W, Coin F, Egly JM, Hoeijmakers JH, Wood RD, Timmers HT, Weeda G. TFIIH with inactive XPD helicase functions in transcription initiation but is defective in DNA repair. J Biol Chem 2000; 275:4258-66. [PMID: 10660593 DOI: 10.1074/jbc.275.6.4258] [Citation(s) in RCA: 131] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
TFIIH is a multisubunit protein complex involved in RNA polymerase II transcription and nucleotide excision repair, which removes a wide variety of DNA lesions including UV-induced photoproducts. Mutations in the DNA-dependent ATPase/helicase subunits of TFIIH, XPB and XPD, are associated with three inherited syndromes as follows: xeroderma pigmentosum with or without Cockayne syndrome and trichothiodystrophy. By using epitope-tagged XPD we purified mammalian TFIIH carrying a wild type or an active-site mutant XPD subunit. Contrary to XPB, XPD helicase activity was dispensable for in vitro transcription, catalytic formation of trinucleotide transcripts, and promoter opening. Moreover, in contrast to XPB, microinjection of mutant XPD cDNA did not interfere with in vivo transcription. These data show directly that XPD activity is not required for transcription. However, during DNA repair, neither 5' nor 3' incisions in defined positions around a DNA adduct were detected in the presence of TFIIH containing inactive XPD, although substantial damage-dependent DNA synthesis was induced by the presence of mutant XPD both in cells and cell extracts. The aberrant damage-dependent DNA synthesis caused by the mutant XPD does not lead to effective repair, consistent with the discrepancy between repair synthesis and survival in cells from a number of XP-D patients.
Collapse
Affiliation(s)
- G S Winkler
- Department of Cell Biology and Genetics, Medical Genetics Center, Erasmus University Rotterdam, P. O. Box 1738, 3000 DR Rotterdam, The Netherlands
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Conrad U, Fiedler U. Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol Biol 1998; 38:101-109. [PMID: 9738962 DOI: 10.1023/a:1006029617949] [Citation(s) in RCA: 174] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Expression and stability of immunoglobulins in transgenic plants have been investigated and optimized by accumulation in different cellular compartments as cytosol, apoplastic space and endoplasmic reticulum (ER) as will be discussed in this review. In several cases described the highest accumulation of complete active antibodies was achieved by targeting into the apoplastic space. High-level expression of active recombinant single-chain Fv antibodies (scFv's) was obtained by retention of these proteins in the lumen of the endoplasmic reticulum. This has been shown for leaves and seeds of transgenic tobacco as well as for potato tubers. Transgenic tobacco seeds, potato tubers and tobacco leaves can facilitate stable storage of scFv's accumulated in the ER over an extended (seeds, tubers) or a short (leaves) period of time. The expression of specific scFv's in different plant species, plant organs and cellular compartments offers the possibility of blocking regulatory factors or pathogens specifically. Examples are scFv's expressed in the cytosol and the apoplastic space of transgenic plant cells modulating the infection process of plant viruses and a cytosolically expressed scFv that influenced the activity of phytochrome A protein. The immunomodulation approach has been shown to be also applicable for investigating the action of the phyto-hormone abscisic acid (ABA). High-level accumulation of specific anti-ABA scFv's in the ER of all leaf cells has been used to block the influence of ABA on the stomatal functions. Seed-specific expression of high amounts of anti-ABA-scFv's at a defined time of seed-development induced a developmental switch from seed ripening to vegetative growth. It has been demonstrated that ER retention is essential for the accumulation of sufficient scFv to bind high concentrations of ABA in the transgenic seeds.
Collapse
Affiliation(s)
- U Conrad
- Institut für Pflanzengenetik und Kulturpflanzenforschung Gatersleben, Germany.
| | | |
Collapse
|
49
|
Bauer E, Recknagel RD, Fiedler U, Wollweber L, Bock C, Greulich KO. The distribution of the tail moments in single cell gel electrophoresis (comet assay) obeys a chi-square (chi2) not a gaussian distribution. Mutat Res 1998; 398:101-10. [PMID: 9626970 DOI: 10.1016/s0027-5107(97)00246-7] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The parameter tail moment in single cell gel electrophoresis (comet assay) is calculated as the product of the two values: the percentage of DNA in the comet tail and the tail length in microm. Experiments were performed with cultured mammalian cells: B-Lymphoblasts, epithelial cells of a kidney tissue and a plate-epithelial cell line of a human carcinoma. They were irradiated in suspension with UV A at lambda = 343 nm, generated by an excimer laser-pumped dye laser. DNA migration was assessed and analysed. It is demonstrated that the distribution of the tail moments can be fitted by a chi2 (chi-square) distribution, whereas the factors of the product tail moment tend to be normally distributed. From this result, consequences for the statistical evaluation of the results can arise, especially for the computation of the confidence limits and for the valuation of the parameter tail moment from other comet assay experiments.
Collapse
Affiliation(s)
- E Bauer
- Institute of Molecular Biotechnology, Jena, Germany.
| | | | | | | | | | | |
Collapse
|
50
|
Goessl C, Knispel HH, Fiedler U, Härle B, Steffen-Wilke K, Miller K. Urodynamic effects of oral oxybutynin chloride in children with myelomeningocele and detrusor hyperreflexia. Urology 1998; 51:94-8. [PMID: 9457296 DOI: 10.1016/s0090-4295(97)00489-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
OBJECTIVES To investigate the effects of oral oxybutynin chloride (OC) on standard urodynamic measures in children with myelomeningocele (MMC) and detrusor hyperreflexia. METHODS Forty-one MMC children with detrusor hyperreflexia (19 boys and 22 girls, aged 2 months to 15 years; mean 4.9 years) were evaluated urodynamically before and within 3 months after initiation of oral OC therapy (0.2 to 0.3 mg/kg/day). Therapy with oral OC was always combined with clean intermittent catheterization (CIC). RESULTS Oral OC treatment caused an increase in bladder capacity from 141 +/- 96 to 197 +/- 99 mL (+ 40%; P < 0.01), a decrease in detrusor pressure at maximal capacity from 45 +/- 32 to 28 +/- 23 cm H2O (-38%; P < 0.01), and an increase in detrusor compliance from 6.5 +/- 5.6 to 16.8 +/- 13.7 mL/cm H2O (+ 158%; P < 0.01). Improvement in urodynamic measures and continence were correlated. After a follow-up of at least 2 years, effective protection of renal function was achieved in 38 of the 41 children (93%) with conservative therapy alone. Adverse effects resulted in discontinuation of oral OC treatment in only 2 cases. CONCLUSIONS Treatment with oral OC and CIC is effective and safe in children with MMC and detrusor hyperreflexia and should be initiated early when indicated by urodynamic findings.
Collapse
Affiliation(s)
- C Goessl
- Department of Urology, Benjamin Franklin Medical Center, Free University of Berlin, Germany
| | | | | | | | | | | |
Collapse
|